Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 681 clinical trials
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy

  • 0 views
  • 24 May, 2021
  • 1 location
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular

  • 0 views
  • 02 Jun, 2021
  • 1 location
  • 0 views
  • 02 Apr, 2021
  • 1 location
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of

  • 0 views
  • 11 Nov, 2021
  • 1 location
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma

This is an Open-label, Single Arm study to observe the safety and tolerability of B010-A in the treatment of advanced hepatocellular carcinoma.

  • 0 views
  • 03 Jan, 2022
  • 1 location
Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma

  • 0 views
  • 11 Nov, 2021
  • 1 location
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

patients with unresectable primary HCC, in the case of failure of TACE treatment, the combination of HAIC, TKI and immunotherapy is expected to bring new breakthroughs.

  • 0 views
  • 03 Dec, 2021
  • 1 location
Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma

A Phase I Clinical Study ofCT0180 cells in Patients with Advanced Hepatocellular Carcinoma

  • 0 views
  • 28 Aug, 2021
  • 1 location
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

types, including patients with advanced hepatocellular carcinoma (HCC). The safety profile and optimal dosage of targeted therapy should be carefully evaluated by clinical trials. Regorafenib is one of

  • 0 views
  • 28 Jan, 2021
  • 1 location
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV

  • 0 views
  • 24 Nov, 2021
  • 1 location